102 related articles for article (PubMed ID: 3070371)
1. Immunologic control of ovarian cancer.
Zighelboim J; Nio Y; Berek JS; Bonavida B
Nat Immun Cell Growth Regul; 1988; 7(4):216-25. PubMed ID: 3070371
[No Abstract] [Full Text] [Related]
2. Activation of peritoneal lymphocyte cytotoxicity in patients with ovarian cancer by intraperitoneal treatment with Corynebacterium parvum.
Lichtenstein A; Berek J; Bast R; Spina C; Hacker N; Knapp RC; Zighelboim J
J Biol Response Mod; 1984 Aug; 3(4):371-8. PubMed ID: 6541243
[TBL] [Abstract][Full Text] [Related]
3. Natural killer inhibitory substance produced by the peritoneal cells of patients with ovarian cancer.
Lichtenstein AK; Berek J; Zighelboim J
J Natl Cancer Inst; 1985 Feb; 74(2):349-55. PubMed ID: 3856049
[TBL] [Abstract][Full Text] [Related]
4. Lymphocytes infiltrating ovarian carcinoma: modulation of functional activity by intraperitoneal treatment with biological response modifiers.
Allavena P; Peri G; Di Bello M; Peccatori F; Chiaffarino F; Pirovano P; Mantovani A
Nat Immun Cell Growth Regul; 1988; 7(4):230-8. PubMed ID: 3070372
[TBL] [Abstract][Full Text] [Related]
5. Intraperitoneal recombinant alpha-interferon for "salvage" immunotherapy in stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study.
Berek JS; Hacker NF; Lichtenstein A; Jung T; Spina C; Knox RM; Brady J; Greene T; Ettinger LM; Lagasse LD
Cancer Res; 1985 Sep; 45(9):4447-53. PubMed ID: 4028027
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy of ovarian cancer.
Creasman WT; Clarke-Pearson DL
Clin Obstet Gynaecol; 1983 Aug; 10(2):297-306. PubMed ID: 6193921
[No Abstract] [Full Text] [Related]
7. Ovarian-tumor-infiltrating lymphocytes: phenotype and antitumor activity.
Lotzová E
Nat Immun Cell Growth Regul; 1988; 7(4):226-9. PubMed ID: 3266295
[No Abstract] [Full Text] [Related]
8. Adoptive cellular immunotherapy of human ovarian carcinoma xenografts in nude mice.
Ortaldo JR; Porter HR; Miller P; Stevenson HC; Ozols RF; Hamilton TC
Cancer Res; 1986 Sep; 46(9):4414-9. PubMed ID: 3089592
[TBL] [Abstract][Full Text] [Related]
9. IL-2 enhances standard IFNgamma/LPS activation of macrophage cytotoxicity to human ovarian carcinoma in vitro: a potential for adoptive cellular immunotherapy.
Han X; Wilbanks GD; Devaja O; Ruperelia V; Raju KS
Gynecol Oncol; 1999 Nov; 75(2):198-210. PubMed ID: 10525372
[TBL] [Abstract][Full Text] [Related]
10. Role of novel adjuvants in specific active immunotherapy.
Cantrell JL; Finn DJ
Prog Clin Biol Res; 1989; 288():297-307. PubMed ID: 2717639
[No Abstract] [Full Text] [Related]
11. Immunologic features of tumor-infiltrating lymphocytes and peripheral blood lymphocytes in ovarian cancer patients.
Schöndorf T; Engel H; Kurbacher CM; Brenne U; Kolhagen H; Göhring UJ; Scharl A; Mallmann P
J Soc Gynecol Investig; 1998; 5(2):102-7. PubMed ID: 9509389
[TBL] [Abstract][Full Text] [Related]
12. Intraperitoneal recombinant alpha 2-interferon for 'salvage' immunotherapy in persistent epithelial ovarian cancer.
Berek JS; Hacker NF; Lichtenstein A; Jung T; Spina C; Knox RM; Brady J; Greene T; Ettinger LM; Lagasse LD
Cancer Treat Rev; 1985 Dec; 12 Suppl B():23-32. PubMed ID: 3833327
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-2 expanded lymphocytes from lymph node and tumor biopsies of human renal cell carcinoma, breast and ovarian cancer.
Bouet-Toussaint F; Genetel N; Rioux-Leclercq N; Bansard JY; Levêque J; Guillé F; Patard JJ; Lesimple T; Catros-Quemener V
Eur Cytokine Netw; 2000 Jun; 11(2):217-24. PubMed ID: 10903800
[TBL] [Abstract][Full Text] [Related]
14. Lymphocyte cytotoxicity in the peritoneal cavity and blood of patients with ovarian cancer.
Berek JS; Bast RC; Lichtenstein A; Hacker NF; Spina CA; Lagasse LD; Knapp RC; Zighelboim J
Obstet Gynecol; 1984 Nov; 64(5):708-14. PubMed ID: 6493663
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic possibilities of virus-modified tumor cell extracts and interleukin-2 in human ovarian cancer.
Lotzová E
Nat Immun Cell Growth Regul; 1986; 5(6):277-82. PubMed ID: 3491956
[No Abstract] [Full Text] [Related]
16. In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer.
Santin AD; Hermonat PL; Ravaggi A; Bellone S; Pecorelli S; Cannon MJ; Parham GP
Am J Obstet Gynecol; 2000 Sep; 183(3):601-9. PubMed ID: 10992180
[TBL] [Abstract][Full Text] [Related]
17. Adoptive immunotherapy of malignant diseases with IL-2-activated lymphocytes.
Kimoto Y; Taguchi T
Biken J; 1987 Jun; 30(2):29-38. PubMed ID: 3501954
[TBL] [Abstract][Full Text] [Related]
18. Lymphokine-activated killer activity of tumor-associated and peripheral blood lymphocytes isolated from patients with ascites ovarian tumors.
Allavena P; Zanaboni F; Rossini S; Merendino A; Bonazzi C; Vassena L; Mangioni C; Mantovani A
J Natl Cancer Inst; 1986 Oct; 77(4):863-8. PubMed ID: 3489856
[TBL] [Abstract][Full Text] [Related]
19. Intraperitoneal administration of human recombinant interferon-alpha in patients with ovarian cancer: effects on lymphocyte phenotype and cytotoxicity.
Lichtenstein A; Spina C; Berek JS; Jung T; Zighelboim J
Cancer Res; 1988 Oct; 48(20):5853-9. PubMed ID: 3167841
[TBL] [Abstract][Full Text] [Related]
20. Chemoimmunotherapy in the management of primary stage III ovarian cancer: a Gynecologic Oncology Group study.
Creasman WT; Gall SA; Blessing JA; Schmidt HJ; Abu-Ghazaleh S; Whisnant JK; DiSaia PJ
Cancer Treat Rep; 1979 Feb; 63(2):319-23. PubMed ID: 445505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
